Kura Oncology Inc (NASDAQ:KURA)’s share price was up 6.5% during mid-day trading on Friday . The stock traded as high as $14.09 and last traded at $13.84, approximately 302,100 shares traded hands during trading. An increase of 13% from the average daily volume of 267,383 shares. The stock had previously closed at $12.99.

Several research analysts have issued reports on KURA shares. ValuEngine lowered shares of Kura Oncology from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 5th. Leerink Swann set a $27.00 price target on shares of Kura Oncology and gave the stock a “buy” rating in a report on Saturday, June 15th. Deutsche Bank started coverage on shares of Kura Oncology in a report on Thursday, July 18th. They set a “buy” rating and a $28.00 price target for the company. BidaskClub lowered shares of Kura Oncology from a “sell” rating to a “strong sell” rating in a report on Wednesday, September 4th. Finally, Zacks Investment Research lowered shares of Kura Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $27.10.

The company has a current ratio of 23.50, a quick ratio of 23.50 and a debt-to-equity ratio of 0.03. The firm’s 50-day moving average price is $15.44 and its 200 day moving average price is $17.02.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.03. Research analysts expect that Kura Oncology Inc will post -1.61 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in KURA. Point72 Hong Kong Ltd acquired a new stake in shares of Kura Oncology during the 2nd quarter worth approximately $25,000. Meeder Asset Management Inc. grew its position in shares of Kura Oncology by 164.9% during the 2nd quarter. Meeder Asset Management Inc. now owns 1,934 shares of the company’s stock worth $38,000 after buying an additional 1,204 shares during the period. Bank of Montreal Can grew its position in shares of Kura Oncology by 82,066.7% during the 2nd quarter. Bank of Montreal Can now owns 2,465 shares of the company’s stock worth $49,000 after buying an additional 2,462 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Kura Oncology by 599.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock valued at $56,000 after purchasing an additional 2,420 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in Kura Oncology in the 2nd quarter valued at $59,000. 85.47% of the stock is owned by institutional investors.

Kura Oncology Company Profile (NASDAQ:KURA)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Read More: Backdoor Roth IRA Conversion and Strategy

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.